By circumventing redundancy in signaling between S6K1/2 and AXL, combination LY-2584702 and BMS-777607 treatment presents a novel kinase-directed approach to capitalize on the vulnerability of PTEN-deficient glioblastomas to inhibit pyrimidine biosynthesis. This evidence concerns the gene AXL and glioblastoma.